Related Experiment Video
Updated: Sep 29, 2025

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
JNK initiates Beclin-1 dependent autophagic cell death against Akt activation
Chao Zeng1, Zhixuan Zhang2, Wei Luo3
1Department of Gastroenterology, The Third People's Hospital of Chengdu, Chengdu, 610031, PR China.
Abstract:
ABT-199, a specific inhibitor of the Bcl-2 protein, is widely used in clinical trials for hematological tumors and rarely applied to the research of solid tumors. In this study, we used Bax/Bak double knockout (KO) and knockdown (KD) cells as the model and found that ABT-199 initiated autophagic cell death independent of Bax and Bak. ABT-199 initiated Beclin-1-dependent autophagy, which led to cell death. Furthermore, inactivated Akt released Beclin-1 from the 14-3-3 protein through a change in the phosphorylation state of Beclin-1 in ABT-199-treated cells. Moreover, JNK antagonized the function of Akt in Beclin-1-mediated autophagy by phosphorylating the 14-3-3 protein. Phosphorylated 14-3-3 exhibited a decreased interaction with Beclin-1. Therefore, ABT-199 activated the JNK-Akt-14-3-3 signaling pathway to mediate the Beclin-1-dependent autophagic death of Bax/Bak KO and KD cells. These findings may extend the therapeutic application of ABT-199 to colon cancer, particularly apoptosis-deficient tumors.
Insights
ABT-199 triggers autophagic cell death in cancer cells lacking Bax and Bak proteins. This process involves the JNK-Akt-14-3-3 pathway and Beclin-1, suggesting potential applications for ABT-199 in apoptosis-resistant solid tumors.
Area of Science:
- Cellular biology
- Molecular oncology
- Cancer research
Background:
- ABT-199 (Venetoclax) is a selective BCL-2 inhibitor primarily investigated for hematological malignancies.
- Its role in solid tumors, especially those with impaired apoptosis, remains less explored.
- Understanding alternative cell death pathways induced by ABT-199 is crucial for expanding its therapeutic potential.
Purpose of the Study:
- To investigate the mechanism of ABT-199-induced cell death in the absence of Bax and Bak.
- To elucidate the role of autophagy in ABT-199 treatment in apoptosis-deficient cells.
- To identify the signaling pathways mediating ABT-199's effects.
Main Methods:
- Utilized Bax/Bak double knockout (KO) and knockdown (KD) cell models.
- Analyzed ABT-199's effect on autophagy and cell death.
- Investigated the involvement of Beclin-1, Akt, and JNK signaling pathways through phosphorylation and protein interaction studies.
Main Results:
- ABT-199 induced Beclin-1-dependent autophagic cell death independently of Bax and Bak.
- Inactivated Akt released Beclin-1 from 14-3-3 protein via altered Beclin-1 phosphorylation.
- JNK activation antagonized Akt by phosphorylating 14-3-3, reducing its interaction with Beclin-1, thus activating autophagy.
Conclusions:
- ABT-199 activates the JNK-Akt-14-3-3 signaling pathway to induce Beclin-1-dependent autophagic cell death in Bax/Bak deficient cells.
- This mechanism highlights a novel route for cancer cell death.
- Findings suggest ABT-199 could be a viable therapeutic option for apoptosis-deficient solid tumors like colon cancer.
More Related Videos
09:18Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death
Published on: December 27, 2016
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
Related Concept Videos
Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
The Intrinsic Apoptotic Pathway
PI3K/mTOR/AKT Signaling Pathway
The Extrinsic Apoptotic Pathway
The JAK-STAT Signaling Pathway
MAPK Signaling Cascades